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Abstract
Background: Blood-vessel dysfunction arises before overt hyperglycemia in type-2 diabetes (T2DM). We hypothesised that a
metabolomic approach might identify metabolites/pathways perturbed in this pre-hyperglycemic phase. To test this
hypothesis and for specific metabolite hypothesis generation, serum metabolic profiling was performed in young women at
increased, intermediate and low risk of subsequent T2DM.
Methods: Participants were stratified by glucose tolerance during a previous index pregnancy into three risk-groups: overt
gestational diabetes (GDM; n= 18); those with glucose values in the upper quartile but below GDM levels (UQ group; n= 45);
and controls (n= 43, below the median glucose values). Follow-up serum samples were collected at a mean 22 months
postnatally. Samples were analysed in a random order using Ultra Performance Liquid Chromatography coupled to an
electrospray hybrid LTQ-Orbitrap mass spectrometer. Statistical analysis included principal component (PCA) and
multivariate methods.
Findings: Significant between-group differences were observed at follow-up in waist circumference (86, 95%CI (79–91) vs
80 (76–84) cm for GDM vs controls, p,0.05), adiponectin (about 33% lower in GDM group, p = 0.004), fasting glucose, post-
prandial glucose and HbA1c, but the latter 3 all remained within the ‘normal’ range. Substantial differences in metabolite
profiles were apparent between the 2 ‘at-risk’ groups and controls, particularly in concentrations of phospholipids (4
metabolites with p#0.01), acylcarnitines (3 with p#0.02), short- and long-chain fatty acids (3 with p,= 0.03), and
diglycerides (4 with p#0.05).
Interpretation: Defects in adipocyte function from excess energy storage as relatively hypoxic visceral and hepatic fat, and
impaired mitochondrial fatty acid oxidation may initiate the observed perturbations in lipid metabolism. Together with
evidence from the failure of glucose-directed treatments to improve cardiovascular outcomes, these data and those of
others indicate that a new, quite different definition of type-2 diabetes is required. This definition would incorporate
disturbed lipid metabolism prior to hyperglycemia.
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Introduction
The metabolic basis of type 2 diabetes mellitus (T2DM) has
traditionally had hyperglycemia as its sine qua non, despite
generally being accompanied by a long prior history of (central)
obesity together with relative physical inactivity. Evidence suggests
that blood vessel dysfunction, either overt or inducible, is
detectable prior to rises in blood glucose [1–3], as occurs in the
disease itself [4]. Debate over whether glucose is the direct cause of
the blood vessel damage has not yet been resolved. Many lines of
evidence suggest that hyperglycemia may not be the earliest
metabolic change in the complications of T2DM. One, based on
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current treatment results in clinical trials, is that complications are
not prevented by glycemic control, intensive or not [5–7],
confirmed by the latest very large trials of dipeptidyl peptidase-4
(DPP-4) inhibitors [8]. Earlier evidence suggested that microvas-
cular components were delayed more by lowered blood pressure
[6,9–11] than by tight blood glucose control. The ACCORD
(Action to Control Cardiovascular Risk in Diabetes) trial reported
no overall difference in microvascular outcomes in diabetic
subjects at risk of cardiovascular events, and intensive glycemic
treatment was associated with higher mortality [12]. HMG CoA
reductase inhibitors with its anti-flammatory and anti-thrombotic
effects [13,14], have been used to target successfully total and
LDL-cholesterol [15,16]. Despite such reductions, intriguingly
statin treatment may marginally increase glycemia [17–19]. A
second line of evidence is that the impaired blood vessel
responsiveness is in both large arteries in vivo [1] and smaller
arteries in tissue biopsy studies, which occurs even when blood
glucose is normal [20]. A third set of arguments, coupled to an
extensive literature reviewed elsewhere, is that iron and copper
dysregulation are implicated in diseases that manifest in changes in
both lipid and carbohydrate metabolism (and their attendant co-
morbidities) [21,22]
Metabolomics is a systems biology strategy for exploring the low
molecular weight metabolites present in the metabolome of an
organism [23]. It portrays a dynamic interaction of a phenotype
with the environment, across genomic and post-transcriptional
regulation [23] and has been applied to study cardiovascular
diseases [24–29] including heart failure [30], myocardial ischemia
[31,32], myocardial infarction [33] and preeclampsia [34]. Its
application in the investigation of glucose intolerance [35–38] has
led to the identification of new metabolic biomarkers and has
highlighted the influence of drugs on the metabolic profile of
subjects diagnosed with glucoregulatory disorders [39,40]. Animal
studies using targeted metabolomic approaches have confirmed
that mitochondrial overload and incomplete fatty acid oxidation in
skeletal muscle occur in both major types of diabetes [41].
Gestational glycemic status including overt gestational diabetes
mellitus (GDM) increases susceptibility to subsequent development
of the T2DM ‘phenotype’ postnatally [42], although a confound-
ing factor is obesity [43].
Here, we examined the early metabolic natural history of ‘pre-
diabetes’ by comparing the serum metabolic profiles of women
from three backgrounds, systematically determined in the third
trimester of pregnancy. However, here, we chose a data-driven
approach free of specific hypotheses [44] to determine which
metabolite classes might be so changed on a number of pathways.
All these women were followed for some two years postnatally
when serum samples for metabolomic analysis were taken. Our
main hypothesis was that the metabolome at follow-up would
differ significantly between those women at high risk of T2DM
(having had previous GDM) compared to those who remained
normoglycemic throughout pregnancy and a third group who
were normoglycemic during pregnancy but in the upper quartile
of the glycemic distribution. Samples of these women were
included in the vascular sub-study [3].
Research Design and Methods
Ethics statement
All protocols were approved by the Central Manchester Local
Research Ethics Committee (LREC No. 03/CM/477: Approval
date 15 June 2004). Participants were fully informed about the
nature, goal, procedures and risks of the study, and gave their
informed consent in writing.
Study Population
The Hyperglycemia and Pregnancy Outcome (HAPO) study
was a multi-centre study investigating the impact of glycemia
below (but not including) overt diabetes in singleton pregnancies of
women not taking anti-hypertensive drugs nor any other chronic
therapies. Inclusion criteria were that women were at least 3
months pregnant, were to deliver at our local maternity hospital,
and had completed a 75 g oral glucose tolerance test (GTT) at 24–
32 weeks gestation.
To establish our sampling frame (Figure 1), we used the
glycemic distribution from the first 957 participants recruited at
Figure 1. The sample selection process.
doi:10.1371/journal.pone.0103217.g001
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the Manchester site of the Hyperglycemia and Pregnancy
Outcome (HAPO) study [45]. From the group of 250 of these
women who were initially followed up, we selected 100 women,
including all 18 with previous GDM and 82 additional participants
by computer-generated random sampling, who were stratified into
the upper quartile of the original glycaemic distribution (UQ
group) or below that distribution’s median (control group). They
were then matched for confounding factors of age, BMI and
ethnicity in that order. There was no prior nor current use of
statins/other cardiometabolic medications in these young women.
The three final study groups were as follows: i) the 18 women who
fulfilled the WHO definition of overt GDM at their HAPO GTT
(GDM group); ii) 39 women with an index gestational fasting
plasma glucose (FPG) value $4.8 but ,5.5 mmol?L21, and/or a
2 hr glucose value of $6.8 but ,7.8, mmol?L21 (i.e. these were
the upper quartile (‘UQ’) cut-off values for the whole distribution
in the 957 original women, below GDM, forming the UQ group);
and iii) 43 women whose gestational FPG had been #4.5, and 2-
hr plasma glucose #5.8, mmol?L21 (from the lower half of the
original GTT distribution) (Control Group) – see Figure 1.
Follow-up was performed at a mean of 22 months after the index
pregnancy when fasting blood serum samples for metabolic
profiling and, if possible, 2-h GTTs were, repeated.
Anthropometric measurements
All anthropometric measurements were taken by trained staff
following WHO guidelines [46]. Total body-fat estimation was via
a widely employed bioimpedance method (Bodystat 1500, Body-
stat Ltd, UK).
Biochemical measurements
Blood samples were centrifuged, and serum and plasma
aliquotted, immediately frozen and maintained at 280uC for
later analysis of lipids and hormones. Blood samples were analyzed
for glucose, triglyceride (TG), total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein choles-
terol (LDL-C), NEFA, insulin, adiponectin, and leptin. We
measured glucose by the glucose oxidase method on a Beckman
Synchron LX system. HbA1c was assayed by reversed phase cation
exchange chromatography (Menarini Diagnostic, UK). Serum
Table 1. Clinical data for participants during pregnancy and at follow-up in the three study groups.
Control UQ GDM F and p values
N 43 39 18
Mean (95% CI) During Pregnancy
*Fasting glucose (mmol.L-1) 4.2 (4.1, 4.3) 4.9 (4.8, 5.0) 4.7 (4.5, 4.8) F = 36.28; p,0.0001
*Two-hour glucose (mmol.L-1) 4.9 (4.7, 5.2) 6.6 (6.3, 6.8) 9.2 (8.9, 9.6) F = 188.29; p,0.0001
At Follow-up
Age (years) 34.9 (33.5, 36.4) 35.6 (34.0, 37.2) 37.1 (34.8, 39.5) NS
Ethnicity n (%)
European 32 (44.4) 29 (40.3) 11 (15.3)
SA 8 (38.1) 6 (28.6) 7 (33.3) NS**
Others 3 (40.0) 4 (60.0) 0 (0)
BMI (kg/m2) 25.3 (23.5, 27.1) 27.6 (25.7, 29.6) 27.6 (24.8, 30.5) NS
Smoking Status (n)
Never 31 22 14
Ex 5 12 2 NS**
Current 7 5 2
Day of cycle (median, IQR) 14 (5–21) 13 (10–15) 19 (14–28) NS
Oral contraceptive use (n) 10 8 5 NS**
Waist circumference (cm) 80 (76, 84) 87 (83, 91) 86 (79, 91) F = 3.22; p= 0.044
Fat (%) 33.5 (31.4, 35.7) 36.5 (34.2, 38.7) 36.5 (33.1, 39.9) NS
HbA1c 4.8 (4.7, 4.9) 5.0 (4.9, 5.1) 5.1 (4.9, 5.2) F = 5.75; p= 0.004
Fasting Glucose (mmol.L–1) 4.8 (4.6, 4.9) 5.0 (4.8, 5.1) 5.1 (4.8, 5.3) F = 3.61; p= 0.031
2h GTT glucose (mmol.L-1) 5.4 (4.8, 5.9) 6.2 (5.6, 6.8) 7.3 (6.5, 8.1) F = 7.83; p = 0.001
NEFA (mmol.L-1) 0.19 (0.16, 0.23) 0.21 (0.17, 0.24) 0.15 (0.10, 0.21) NS
Total Cholesterol (mmol.L-1) 4.4 (4.1, 4.6) 4.2 (4.0, 4.6) 4.2 (3.8, 4.6) NS
LDL-C (mmol.L-1) 2.5 (2.3, 2.8) 2.5 (2.2, 2.7) 2.5 (2.1, 2.9) NS
HDL-C (mmol.L-1) 1.46 (1.34, 1.59) 1.35 (1.22, 1.47) 1.34 (1.15, 1.52) NS
Triglycerides (mmol.L-1) 0.8 (0.7, 0.9) 1.0 (0.9, 1.1) 0.9 (0.7, 1.1) NS
#Fasting Insulin (pmol/L) 6.1 (4.9, 7.7) 5.7 (4.5, 7.2) 6.9 (4.9, 9.7) NS
#Adiponectin (mg/L) 3.5 (3.0, 4.1) 3.0 (2.6, 3.5) 2.3 (1.9, ) F = 5.78; p = 0.004
Leptin (ng/mL) 19.0 (13.6, 24.5) 25.4 (19.8, 31.1) 22.9 (14.7, 31.1) NS
p values calculated applying ANOVA or **Chi-squared tests. #Data are geometric mean and 95% confidence intervals
doi:10.1371/journal.pone.0103217.t001
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Table 2. Metabolites that differed significantly between control and UQ groups at 2-y follow-up (p,0.05).
Metabolite Molecular mass p-value Ratio
(monoisotopic mass) (UQ:glycemic control)
PHOSPHOLIPIDS
PC(34:0) 759.5778 0.0092 0.81 (0.70, 0.94)
PC(34:3) 755.5465 0.0114 0.75 (0.57, 0.97)
PG(40:4) 826.5724 0.0144 0.92 (0.86, 0.98)
PC(18:1/dm18:1) AND/OR PC(18:2/dm18:0) 769.5985 0.0162 0.84 (0.71, 0.99)
PC(16:0/dm18:1) AND/OR PC(16:1/dm18:0) AND/OR PC(18:1/dm16:0) 743.5829 0.0226 0.81 (0.68, 0.98)
PS(20:0) 567.3172 0.0304 0.84 (0.73, 0.97)
PC(32:3) 727.5152 0.0317 0.81 (0.70, 0.95)
PC(18:0) 509.3845 0.0323 0.80 (0.67, 0.97)
PC(31:1) 717.5309 0.0339 0.86 (0.77, 0.97)
PE(42:2) 827.6404 0.0363 0.88 (0.78, 0.98)
PC(16:0/dm18:1) AND/OR PC(16:1/dm18:0) AND/OR PC(18:1/dm16:0) AND/OR PC(34:2) 743.5829 0.0406 0.85 (0.74, 0.98)
PC(16:0) 481.3532 0.0485 0.86 (0.75, 0.99)
LONG CHAIN FATTY ACIDS AND RELATED METABOLITES
Arachidonic acid * 304.2402 0.0128 0.86 (0.75, 0.98)
Hydroxy-dodecanoic acid 216.1725 0.0281 0.91 (0.82, 1.01)
N-(3-(hexadecanoyloxy)-heptadecanoyl)-ornithine 638.5598 0.0309 0.83 (0.71, 0.98)
Hydroxy-dodecadienoic acid AND/OR Oxo-dodecenoic acid 212.1412 0.0327 0.91 (0.78, 1.04)
Octadecadienoic acid * 280.2402 0.0385 0.85 (0.72, 1.01)
1,11-Undecanedicarboxylic acid AND/OR Methyl-dodecanedioic acid 244.1675 0.0496 0.91 (0.82, 1.01)
11-deoxy-PGE1 AND/OR 11-deoxy-PGF2 AND/OR 15-hydroperoxyeicosatrienoic acid 338.2457 0.0495 1.41 (0.88, 2.35)
SHORT CHAIN FATTY ACIDS AND RELATED METABOLITES
Glyoxylic acid * 73.9993 0.0307 0.92 (0.86, 0.99)
Dimethylmalic acid AND/OR Ethylmalic acid AND/OR Hydroxyadipic acid 162.0528 0.0056 1.05 (0.97, 1.12)
Dimethylbutenoic acid 114.0681 0.0160 1.04 (0.95, 1.14)
2-Methylmaleic acid AND/OR Acetylpyruvic acid AND/OR Glutaconic acid AND/OR
Itaconic acid AND/OR Mesaconic acid 130.0266 0.0249 1.03 (0.99, 1.08)
Methylacetoacetic acid 116.0473 0.0355 1.03 (0.97, 1.09)
2-Butenoic acida AND/OR Amino-methylpropanoic acidb AND/OR Aminobutanoic acidb 86.03678a;103.063329b 0.0376 1.18 (0.96, 1.43)
ACETYLCARNITINES
Dodecanoylcarnitine 343.2723 0.0123 0.75 (0.60, 0.93)
Octanoylcarnitine 287.2097 0.0200 0.79 (0.64, 0.97)
Decanoylcarnitine 315.2410 0.0210 0.77 (0.62, 0.95)
Tetradecanoyl carnitine 369.2879 0.0388 0.77 (0.60, 0.98)
DIGLYCERIDES
DG(35:0) 610.5536 0.0232 0.85 (0.74, 0.98)
DG(34:0) 596.5380 0.0454 0.92 (0.85, 1.00)
DG(33:0) 582.5223 0.0474 0.90 (0.81, 0.99)
DG(40:3) 674.5849 0.0496 0.84 (0.72, 0.99)
BILE ACIDS
24-Nor-5beta-cholane-3alpha,12alpha,22,23-tetrol AND/OR isomer 380.2927 0.0259 0.79 (0.65, 0.96)
STEROIDS, PROSTANOIDS AND RELATED METABOLITES
Pregnane AND/OR
2alpha-(Hydroxymethyl)-17-methyl-5alpha-androstane-3beta,17beta-diol
AND/OR 5beta-Pregnane-3alpha,17alpha,20alpha-triol 336.2664 0.0066 0.78 (0.64, 0.95)
Leukotriene C5 623.2866 0.0340 0.86 (0.74, 1.00)
3beta-Hydroxyandrost-5-en-17-one 3-
sulfatea AND/OR 15-Hydroxy-5,8,11-cis-13-trans- eicosatetraenoic acidb 368.165746a;320.235145b 0.0172 1.36 (1.08, 1.70)
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adiponectin and leptin were measured using ELISA (R&D
Systems, Minneapolis, MN), and insulin with monoclonal-based
ELISAs (Mercodia, Sweden). Serum TC and TG were measured
by the CHOD/PAP and GPO/PAP methods respectively on a
Cobas Mira S analyzer (ABX Diagnostics, Shefford, UK); all
reagents were obtained from the same source. HDL-C was
measured by a second-generation homogenous method using
PEG-modified enzymes (Roche Diagnostics, Lewes, UK). LDL-C
was calculated using the Friedewald formula. A calculated LDL-C
value of ,0.1 mmol.L21 was set as the detection limit for
cholesterol. Finally, we measured non-esterified free fatty acids
(NEFA) in plasma using an enzymatic endpoint assay (WAKO
Chemicals, Richmond VA) with a detection limit of
0.01 mmol.L21.
Preparation of serum samples for metabolomic analysis
Fasting serum samples taken at follow-up, with group of origin
blinded to the analyst, were thawed on ice and prepared as
previously described [47,48]. Samples were deproteinised by
mixing 200-mL plasma with 600-mL methanol followed by vortex-
mixing (15 s) and centrifugation (15 min, 13,865 g). 370-mL
aliquots of each supernatant were transferred to two Eppendorf
tubes and lyophilised (HETO VR MAXI vacuum centrifuge
attached to a Thermo Svart RVT 4104 refrigerated vapour trap;
Thermo Life Sciences, Basingstoke, UK). The aliquots were for
separate positive- and negative-ion Ultra Performance Liquid
Chromatography-Mass Spectrometry (UPLC-MS) analyses, re-
spectively. A pooled quality control (QC) sample [47] was also
prepared by mixing 50-mL aliquots of serum from each of 100
subject samples followed by vortex mixing for one minute. 200-mL
aliquots of the pooled QC sample were deproteinised and
lyophilised as described above.
UPLC-MS analysis
Each sample was reconstituted in 100-mL water and vortex
mixed (15 s) and then centrifuged (15 min, 13,865 g). Samples
were analysed in a random order using Ultra Performance Liquid
Chromatography (UPLC; Waters, Elstree, UK) coupled to an
electrospray hybrid LTQ-Orbitrap mass spectrometer (Thermo-
Fisher Scientific, Bremen, Germany). Each sample was analysed
twice, once in negative-ion mode and once in positive-ion mode.
The analytical conditions [47,49] and application of QC samples
[47] were applied as described previously.
Raw data processing and data analysis
Raw data files (.RAW) were converted to the NetCDF format
using the File converter program in XCalibur (ThermoFisher
Scientific, Bremen, Germany). Deconvolution of data was
performed using XCMS as described previously [48], as were
signal correction and quality assurance procedures [34].
Statistical analysis
Statistical analyses were carried out using STATA version 12
(Stata Corporation, College Station, Texas) or programs written in
the MatlabH scripting language (version 7.8; http://www.
mathworks.com/). Summary statistics of non-normally distributed
continuous variables are presented as geometric means – derived
from log-transformed data. Univariate analysis was performed
using the Mann-Whitney U test, a non-parametric method for
assessing whether two independent samples come from the same
distribution. We used maximum-likelihood multinomial logit
models to assess the relationship between levels of adiponectin,
leptin, indices of adiposity (BMI), smoking status, triglyceride, non-
esterified fatty acids (NEFA) as well as cholesterol and the
likelihood of having GDM or the UQ of glycemia compared to the
control group. Missing values were ignored.
Annotation of putative metabolites matched to features
Metabolic features characterized by measuring both the
accurate m/z and retention time, and corresponding putative
molecular annotations were assigned by standard methods as
described [50]. One or more molecular formulae within available
databases were assigned to each feature with mass accuracy of
63 ppm. These were subsequently searched against The Man-
chester Metabolomics Database, which has been constructed with
information from the Human Metabolome Database (http://
www.hmdb.ca/, v2.0) and Lipidmaps (http://www.lipidmaps.
org/). This is a level 2 annotation according to the proposed
reporting standards of the Metabolomics Standards Initiative [51].
In these types of raw metabolomic data, a single metabolic feature
can be assigned to one or more metabolites due to uncertainty
caused by possible isomerism, resulting in a non-specific annota-
Table 2. Cont.
Metabolite Molecular mass p-value Ratio
(monoisotopic mass) (UQ:glycemic control)
AMINO ACIDS AND RELATED METABOLITES
Proline Betaine 143.0946 0.0181 0.94 (0.89, 0.99)
Urea * 60.03240 0.0388 0.92 (0.82, 1.03)
Thiourocanic acid 170.0150 0.0408 0.93 (0.87, 1.00)
OTHERS
3-Deoxyvitamin D3 368.3443 0.0309 0.81 (0.67, 0.97)
Enterostatin (VPGPR) 524.3071 0.0405 0.78 (0.62, 1.00)
Decanol 158.1671 0.0454 1.03 (0.99, 1.07)
Metabolites have been classified into structural or functional classes. Within each class, data have been separated into those with higher (where such exist) and lower
ratios, respectively, and are then presented in order from lowest to highest p value. The molecular weights, calculated as the monoisotopic mass, are included. Ratios
with 95% confidence intervals in parentheses are shown. DM, demethyl, G, glycine; P, proline; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG,
glycerophosphoglycerol; PS, phosphatidylserine; R, arginine; V, valine; The values in parentheses (for example PC(34:0)) relate to the total fatty acid carbon chain length
and number of carbon double bonds (unsaturation) in each metabolite. *Identification by matching of retention time and accurate mass to authentic chemical standard
doi:10.1371/journal.pone.0103217.t002
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Table 3. Metabolites differing between control and GDM groups at 2-y follow-up (p,0.05).
Metabolite Molecular mass p-value Ratio
(monoisotopic mass) (GDM:glycemic control)
PHOSPHOLIPIDS
LysoPC(10:1) 395.2437 0.0114 0.79 (0.58, 1.01)
PI(36:3) 860.5415 0.0188 0.90 (0.83, 0.97)
PC(34:0) 747.6142 0.0206 0.81 (0.69, 0.94)
PC(38:0) 817.6561 0.0328 0.80 (0.66, 0.96)
LysoPC(16:2) 477.3219 0.0481 0.88 (0.77, 1.01)
LysoPE(18:1) 479.3012 0.0489 0.83 (0.69, 0.99)
LysoPC(20:1) 549.3794 0.0430 1.03 (1.00, 1.06)
LysoPG(18:1) 510.2958 0.0499 1.04 (0.86, 1.26)
PS(37:0) 805.5833 0.0291 1.09 (1.01, 1.16)
LONG CHAIN FATTY ACIDS AND RELATED METABOLITES
Tetradecenoic acid * 226.1933 0.0142 0.91 (0.86, 0.97)
Decadiynoic acid 164.0837 0.0203 0.58 (0.40, 0.85)
Hydroxydodecanoic acid 216.1725 0.0303 0.71 (0.56, 0.90)
Hydroxyoctadecanoic acid 300.2664 0.0312 0.74 (0.63, 0.89)
Docosanol 326.3549 0.0394 0.79 (0.66, 0.95)
3-Isopropenyl-6-oxoheptanoic acid AND/OR Oxodecenoic acid 184.1099 0.0073 1.38 (1.05, 1.80)
Decanol 158.1671 0.0109 1.07 (1.00, 1.13)
Nonadienoic acid 154.0994 0.0181 1.11 (1.03, 1.20)
Elaidoylamide 281.2719 0.0202 1.09 (0.96, 1.24)
Octenedioic acid AND/OR Dioxo-octanoic acid 172.0736 0.0250 1.21 (0.93, 1.49)
Hydroxydodecanoic acid 216.1725 0.0487 1.23 (0.89, 1.65)
SHORT CHAIN FATTY ACIDS AND RELATED METABOLITES
Hydroxypyruvic acid AND/OR Malonic acid 104.0110 0.0029 0.92 (0.86, 0.97)
Acetic acida AND/OR Glyceric acidb 60.02113a;106.02661b 0.0114 0.92 (0.87, 0.98)
Methylmalonic acid semialdehyde AND/OR Methyloxopropanoic acid 102.0317 0.0125 0.93 (0.88, 0.98)
Propanoic acida AND/OR Dihydroxybutyric acidb AND/OR Deoxyerythronic acidb 74.03678a;120.04226b 0.0237 0.93 (0.87, 0.99)
2-Amino-3-phosphonopropanoic acida AND/OR 2-hydroxysuccinamic acidb 169.014011a;133.037509b 0.0254 0.62 (0.44, 0.89)
Methylvaleric acid AND/OR Dimethylbutanoic acid 116.0837 0.0470 0.82 (0.66, 0.99)
Dimethylmalic acid AND/OR Ethylmalic acid AND/OR Hydroxyadipic acid 162.0528 0.0024 1.11 (1.02, 1.22)
8-Amino-7-oxononanoate 187.1208 0.0049 1.49 (1.17, 1.98)
Butenoic acid *
AND/OR Oxobutanoic acid AND/OR Methylpyruvic acid 84.0211 0.0079 1.16 (1.04, 1.28)
Ethylhexenoic acid AND/OR Methylheptenoic acid AND/OR Octenoic acid 142.0994 0.0139 1.25 (1.06, 1.48)
Oxopentanoic acid AND/OR Methyloxobutanoic acid 116.0473 0.0241 1.21 (1.01, 1.42)
Oxo-hydroxy-aminovaleric acid 147.0532 0.0350 1.32 (1.03, 1.65)
Methylmaleic acid AND/OR Acetylpyruvic acid AND/OR
Itaconic acid AND/OR Mesaconic acid 130.0266 0.0445 1.03 (0.99, 1.08)
Hydroxyhexanoic acid AND/OR Ethyl-Hydroxybutyric acid AND/OR
Hydroxymethylpentanoic acid 132.0786 0.0481 1.18 (0.93, 1.48)
DIGLYCERIDES
DG(40:1) 678.6162 0.0167 0.78 (0.66, 0.93)
BILE ACIDS
Chenodeoxycholic acid 3-sulphate 472.2495 0.0279 0.87 (0.76, 1.00)
3alpha,12alpha-Dihydroxy-5beta-chol-22-en-24-oic Acid
AND/OR isomers 390.2770 0.0481 0.94 (0.87, 1.00)
5beta-Cholane-3alpha-24-diol 410.3185 0.0108 1.10 (1.02, 1.18)
STEROIDS, PROSTANOIDS AND RELATED METABOLITES
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tion. A higher confidence of a unique annotation can be
performed, where experimentally feasible, if the accurate mass,
collision-induced dissociation mass spectra and retention time are
matched with that of an authentic chemical standard analysed
under identical analytical conditions. This is considered to be a
level 1 identification according to the reporting standards defined
by the Metabolomics Standards Initiative [51]. Where more than
one putative structure can be assigned to any analytical feature
corresponding to a particular molecular mass (that is, more than
one molecule of the particular mass could occur in physiology),
each possible annotation has been listed with ‘AND/OR’ as the
conjunction. To minimise the influence of false discovery we
Table 3. Cont.
Metabolite Molecular mass p-value Ratio
(monoisotopic mass) (GDM:glycemic control)
4alpha,24beta-Dimethyl-5alpha-cholest-22-en-3beta-4beta-diol AND/OR
4alpha-hydroxymethyl-4beta-methyl-5alpha-cholesta-8-en-3beta-ol
AND/OR isomers 430.3811 0.0131 0.78 (0.63, 0.95)
25-Azacholesterol 387.3501 0.0499 0.93 (0.83, 1.05)
PGF2alpha-11-acetate 396.2512 0.0025 1.11 (1.03, 1.19)
11alpha-hydroxy-9,15-dioxoprost-13-enoate 352.2250 0.0054 1.12 (1.02, 1.24)
3alpha,11beta,17alpha-Trihydroxy-5beta-pregnan-20-one AND/OR isomers 350.2457 0.0499 1.07 (0.99, 1.15)
AMINO ACIDS AND RELATED METABOLITES
N-(Aminomethyl)urea 89.0589 0.0045 0.52 (0.35, 0.80)
Phosphoshikimate 254.0192 0.0104 0.85 (0.76, 0.95)
Tryptophan * 204.0899 0.0139 0.90 (0.83, 0.98)
Uric acid * 168.0283 0.0177 1.11 (1.02, 1.20)
Proline * 115.0633 0.0185 1.09 (0.90, 1.36)
Leucine AND/OR Isoleucine AND/OR Norleucine AND/OR N-methylvaline 131.0946 0.0268 1.27 (1.02, 1.54)
Dimethyluric acid 196.0596 0.0365 1.17 (1.01, 1.36)
UBIQUINONE AND STEROL BIOSYNTHESIS AND RELATED METABOLITES
2-Polyprenylphenol 230.1671 0.0107 0.69 (0.44, 1.02)
Benzosemiquinone 110.0368 0.0346 0.56 (0.38, 0.88)
2-Hexaprenylphenol 502.4175 0.0368 0.89 (0.81, 0.97)
TETRAHYDROFOLATE METABOLISM
5,6,7,8-Tetrahydrofolate 445.1710 0.0206 0.84 (0.68, 1.01)
5-Methyltetrahydropteroyltriglutamate 717.2718 0.0041 1.21 (1.00, 1.46)
OTHERS
Glucosylceramide(42:1) 811.6901 0.0051 0.81 (0.68, 0.96)
Pantetheine 4’-phosphatea AND/OR N-((R)-Pantothenoyl)-L-cysteineb 358.096361a;322.119859b 0.0079 0.94 (0.90, 0.97)
Teasterone AND/OR Typhasterol 448.3553 0.0279 0.80 (0.65, 0.95)
Methylguanosine 297.1073 0.0369 0.91 (0.85, 0.98)
Methylglucuronic Acida AND/OR Dihydrolipoic acidb 208.058305a;208.059172b 0.0006 1.13 (1.02, 1.25)
Propane-1,2-diol-1-phosphatea AND/OR 2-Hydroxy-2-methylbutyric acidb 156.018762a;118.062995b 0.0034 1.59 (1.13, 2.18)
Thiourocanic acid 170.0150 0.0042 1.16 (1.05, 1.27)
Nonylglucoside 306.2042 0.0070 1.61 (1.05, 2.24)
CDP-4-dehydro-6-deoxy-D-glucose 547.0604 0.0108 1.10 (1.01, 1.21)
Monosaccharide 180.0634 0.0136 1.14 (1.03, 1.27)
5,7,22,24(28)-ergostatetraenola AND/OR
20-cyclopropyl-1alpha,25-dihydroxy-16,17-didehydro-21-norvitamin D3
b 394.323565a;440.329045b 0.0185 1.38 (1.02, 1.81)
Ribose 1,5-bisphosphate AND/OR isomer 309.9855 0.0365 1.13 (1.00, 1.27)
CE(15:0) 610.5689 0.0400 1.27 (0.95, 1.66)
Metabolites have been classified according to their molecular structures or known metabolic functions/pathway participation. Within each class the data have been
separated in to those with higher and lower ratios and are then presented in order from lowest to highest p value. The molecular weights, calculated as the
monoisotopic mass, are included. Ratios with 95% confidence intervals in parentheses are shown. CE cholesteryl ester; DG, diglyceride; PC, phosphatidylcholine; PE,
phosphatidylethanolamine; PG, phosphatidylglycine; PGF, prostaglandin; PI, phosphatidylinositol; PS, phosphatidylserine; The values in parentheses (for example
PC(34:0)) relate to the total fatty acid carbon chain length and number of carbon double bonds (unsaturation) in each metabolite. *Identification by matching of
retention time and accurate mass to authentic chemical standard.
doi:10.1371/journal.pone.0103217.t003
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Table 4. Metabolites differing between UQ and GDM groups at 2-y follow-up (p,0.05).
Metabolite Molecular mass p-value Ratio
(monoisotopic mass) (GDM:UQ)
PHOSPHOLIPIDS
LysoPC(16:2) 477.3219 0.0196 0.88 (0.77, 0.99)
PC(36:3) 767.5829 0.0378 0.91 (0.83, 0.99)
PG(40:5) 824.5567 0.0056 1.17 (1.01, 1.35)
PC(48:1) 759.5778 0.0099 1.19 (1.00, 1.40)
LysoPC(18:0) 523.3638 0.0214 1.11 (0.97, 1.27)
PC(19:0) 537.3794 0.0234 1.31 (1.00, 1.67)
PC(32:3) 727.5152 0.0287 1.16 (1.01, 1.32)
LysoPC(16:0) 495.3325 0.0292 1.07 (0.99, 1.16)
PC(14:1/dm16:0)a AND/OR PE(15:0/dm18:1)b AND/OR PC(34:6)b 687.520291a;749.499556b 0.0301 1.13 (1.01, 1.27)
PC(36:1) 787.6091 0.0347 1.13 (0.98, 1.31)
PC(17:0) 509.3481 0.0411 1.25 (1.00, 1.55)
LONG CHAIN FATTY ACIDS AND RELATED METABOLITES
Tetradecenoic acid * 226.1933 0.0037 0.90 (0.84, 0.96)
Eicosanol 298.3236 0.0305 0.87 (0.80, 0.96)
Dimethylundecanoic acid AND/OR Methyldodecanoic acid 214.1933 0.0445 0.86 (0.74, 0.99)
Tridecadienoic acid 210.1620 0.0045 1.21 (1.06, 1.38)
Octadecadienol 266.2610 0.0047 1.20 (1.06, 1.36)
Nonadienoic acid 154.0994 0.0134 1.81 (1.28, 2.52)
Elaidoylamide 281.2719 0.0215 1.12 (0.97, 1.28)
Hydroxydodecadienoic acid AND/OR Oxododecenoic acid 212.1412 0.0256 1.08 (1.01, 1.15)
Nonadienoic acid * 154.0994 0.0269 1.11 (1.02, 1.19)
Hexacosatrienoic acid * 390.3498 0.0419 1.66 (0.98, 2.46)
Hydroxydecanoic acid 188.1412 0.0446 1.23 (0.95, 1.54)
SHORT CHAIN FATTY ACIDS AND RELATED METABOLITES
Hydroxypyruvic acid AND/OR Malonic acid 104.0110 0.0035 0.91 (0.86, 0.97)
Acetic acid AND/OR Glyceric acid 60.02113a;106.02661b 0.0205 0.93 (0.87, 0.98)
Methylmalonic acid semialdehyde AND/OR Methyl-oxopropanoic acid
AND/OR Oxobutanoic acid AND/OR Methylpyruvic acid 102.0317 0.0280 0.93 (0.88, 0.99)
Methylvaleric acid AND/OR Dimethylbutanoic acid 116.0837 0.0329 0.81 (0.66, 0.98)
Propanoic acida AND/OR Dihydroxybutyric acidb AND/OR Deoxyerythronic acidb 74.03678a;120.04226b 0.0362 0.93 (0.86, 0.99)
Diaminopropanoic acida AND/OR Hydroxy-oxoglutaric acidb 104.058578a;162.01644b 0.0378 0.93 (0.87, 1.00)
Hydroxyheptynoic acid 142.0630 0.0484 0.91 (0.83, 1.00)
Decadiynoic acid 164.0837 0.0498 0.70 (0.50, 0.97)
Isopropenyl-oxoheptanoic acid AND/OR Oxodecenoic acid 184.1099 0.0066 1.26 (0.86, 2.09)
Hydroxyheptanoic acid 146.0943 0.0181 1.14 (1.01, 1.28)
Butynoic acid 84.0211 0.0268 1.11 (1.00, 1.22)
Amino-oxononanoic acid 187.1208 0.0287 1.29 (1.00, 1.71)
Oxopentanoic acid AND/OR Methyl-oxobutanoic acid 116.0473 0.0413 1.17 (0.98, 1.38)
Octenedioic acid AND/OR Dioxo-octanoic acid 172.0736 0.0480 1.15 (0.88, 1.45)
DIGLYCERIDES
DG(32:0) 568.5067 0.0319 1.13 (1.01, 1.25)
DG(34:0) 624.5693 0.0333 1.15 (1.01, 1.30)
DG(43:3) 718.6475 0.0378 1.08 (0.97, 1.20)
DG(36:1) 610.5536 0.0481 1.23 (0.98, 1.50)
BILE ACIDS
Chenodeoxycholic acid 3-sulfate 472.2495 0.0347 0.88 (0.76, 1.01)
3alpha,12alpha-Dihydroxy-5beta-chol-22-en-24-oic Acid AND/OR isomers 390.2770 0.0446 0.91 (0.84, 1.00)
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grouped metabolites based on biological function or chemical
structure. The relative ‘hierarchies by p value’ are shown in the
Result Tables. We performed univariate as well as unsupervised
multivariate analyses using principal component analyses (PCA).
PCA showed no clustering related to class or sub-clustering of
subjects from one or multiple classes therefore these data were not
included in the manuscript. Similarly, Partial Least Squares –
Discriminant analyses (PLS-DA) was also performed but no
Table 4. Cont.
Metabolite Molecular mass p-value Ratio
(monoisotopic mass) (GDM:UQ)
Glycochenodeoxycholic acid 3-glucuronide 625.3462 0.0484 0.49 (0.23, 1.03)
5-beta-Cholane-3alpha,24-diol 410.3185 0.0002 1.16 (1.08, 1.24)
STEROIDS, PROSTANOIDS AND RELATED METABOLITES
4alpha,24beta-Dimethyl-5alpha-cholest-22-en-3beta-4beta-diol AND/OR
4alpha-hydroxymethyl-4beta-methyl-5alpha-cholesta-8-en-3beta-ol AND/OR isomers 430.3811 0.0051 0.75 (0.60, 0.91)
25-Azacholesterol 387.3501 0.0428 0.95 (0.85, 1.06)
Leukotriene C5 623.2866 0.0032 1.28 (1.10, 1.50)
11alpha-Hydroxy-9,15-dioxoprost-13-enoate 352.2250 0.0035 1.18 (1.06, 1.30)
PGF2alpha-11-acetate 396.2512 0.0095 1.12 (1.03, 1.23)
11beta-Hydroxyprogesterone AND/OR 17beta-Hydroxy-4-oxa-5alpha-androst-1-en-3-one acetate
AND/OR 5,6-epoxy,18R-HEPE 332.1988 0.0160 1.24 (0.90, 1.72)
AMINO ACIDS AND RELATED METABOLITES
N-(Aminomethyl)urea 89.0589 0.0023 0.60 (0.44, 0.83)
Phosphoshikimate 254.0192 0.0116 0.84 (0.74, 0.95)
Hydantoin 100.0273 0.0428 0.96 (0.92, 1.00)
Tryptophan * 204.0899 0.0171 0.90 (0.82, 0.98)
Methylcrotonylglycine AND/OR Tiglylglycine 157.0739 0.0448 0.51 (0.28, 0.93)
Proline * 115.0633 0.0048 1.10 (1.03, 1.19)
2-Oxoglutaramate 145.0375 0.0154 2.11 (0.79, 3.96)
Leucine OR Isoleucine AND/OR Norleucine AND/OR N-methylvaline 131.0946 0.0464 1.21 (0.96, 1.50)
UBIQUINONE AND STEROL BIOSYNTHESIS AND RELATED METABOLITES
2-Hexaprenylphenol 502.4175 0.0105 0.88 (0.81, 0.97)
2-Polyprenylphenol 230.1671 0.0220 0.72 (0.46, 1.05)
5-Phosphomevalonate 228.0399 0.0245 0.92 (0.84, 1.00)
Benzosemiquinone 110.0368 0.0464 0.67 (0.48, 0.93)
2-trans,6-trans-Farnesal OR 4-n-Nonylphenol 220.1827 0.0446 1.23 (0.93, 1.55)
TETRAHYDROFOLATE METABOLISM
5,6,7,8-Tetrahydrofolate 445.1710 0.0131 0.86 (0.70, 1.02)
OTHERS
Hydroxycholesterol AND/OR 12,14-Heptacosadiynoic acid AND/OR
12alpha-Hydroxy-5beta-cholestan-3-one AND/OR 19-Hydroxy-10S,19-dihydrovitamin D3 402.3498 0.0111 0.77 (0.64, 0.93)
Pantetheine 4’-phosphatea AND/OR N-((R)-Pantothenoyl)-L-cysteineb 358.096361a;322.119859b 0.0292 0.95 (0.92, 0.99)
CE(16:2) 620.5532 0.0464 0.93 (0.80, 1.07)
CE(15:0) 610.5689 0.0061 1.28 (0.94, 1.73)
CDP-4-dehydro-6-deoxy-D-glucose 547.0604 0.0070 1.12 (1.02, 1.22)
14-methyl-20,14-retro-retinoic acid AND/OR 16,17-Didehydropregnenolone AND/OR
17beta-Hydroxy-2alpha,17-dimethyl-4,9(11)-androstadien-3-one AND/OR isomers 314.2246 0.0179 1.28 (0.93, 1.77)
Hexose sugar 180.0634 0.0214 1.12 (1.01, 1.24)
Alpha-CEHC-glucuronide 454.1839 0.0458 1.10 (0.99, 1.20)
Metabolites have been classified according to their molecular structures or known metabolic functions/pathway participation. Within each class, data have been
separated in to those with higher and lower ratios and are then presented in order from lowest to highest p value. The molecular weights, calculated as the
monoisotopic mass, are included. Ratios with 95% confidence intervals in parentheses are shown. CE Cholesteryl ester; CEHC, 2,5,7,8-tetramethyl-2-(2’-carboxyethyl)-6-
hydroxychroman; DG, diglyceride; HEPE, hydroxy-eicosapentaenoic acid; PC, phosphatidylcholine; PG, phosphatidylglycine; The values in parentheses (for example
PC(34:0)) relate to the total fatty acid carbon chain length and number of carbon double bonds (unsaturation) in each metabolite. *Identification by matching of
retention time and accurate mass to authentic chemical standard.
doi:10.1371/journal.pone.0103217.t004
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validated models were constructed and therefore these data were
not reported.
Results
Subject group characteristics
Standard anthropometric and metabolic parameters were
measured in all participants, and stratified by glycemic status
(Table 1). No significant between-group differences were present
in age, ethnicity, BMI nor smoking status at follow-up. Small but
significant differences in fasting and two-hour serum glucose
concentrations occurred during pregnancy as expected. Significant
between-group differences were observed at follow-up in waist
circumference, adiponectin, fasting glucose, post-prandial glucose
and HbA1c, with means and all ranges are still within the ‘normal’
range (as defined by WHO), between control and both UQ and
GDM women.
In maximum-likelihood multinomial logit models, increasing
adiponectin concentrations (60% reduction in risk per mg.L21)
was independently associated with a GDM classification compared
to control (Relative risk ratios: 0.41 (0.22, 0.78), p = 0.005) in a
model including age (1.16 (1.00, 1.37)), BMI (1.03 (0.86, 1.24)),
history of smoking (0.75 (0.93, 1.99)), Ln NEFA (0.85 (0.29, 2.50)),
total cholesterol (0.87 (.38, 1.99)), leptin (0.99 (0.93, 1.07) and
triglycerides (0.49 (0.11, 2.18)).
Between-group differences in metabolite concentrations
3,552 metabolomic features were judged suitable for univariate
analysis after raw metabolite data and related quality assurance
processes had been performed. Levels of numerous metabolites
differed significantly between groups. Data are presented
(Tables 2 to 4), according to a metabolite classification system in
which each molecule is listed as a member either of a structural
class (e.g. ‘short-chain fatty acids and related metabolites’) or a
functional class according to its participation in a defined
metabolic process (e.g. ,participating in. ‘tetrahydrofolate
metabolism’). Each metabolite has been listed only once as a
member of a single class. If a metabolite was detected more than
once, the feature with the lowest p value was reported. Within
each class, data have been separated into those with higher and
lower ratios and are then presented in order from lowest to highest
p-value. Figure 2 shows in ascending order of fold difference, the
top 32 metabolites for all three comparisons.
By comparing the control and UQ groups, 173 of 3552
metabolic features were statistically different (p,0.05). Of these,
43 unique metabolic features were annotated (Table 2). 35
Figure 2. Fold differences metabolites for top 32 metabolites with lowest p values at 2-y follow-up. Metabolites have been classified
into classes (*control vs UQ, **control vs GDM and ***UQ vs GDM). Data are in ascending order (lowest to those with the highest) of the ratio of
difference between groups. All have p values of ,0.01.
doi:10.1371/journal.pone.0103217.g002
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metabolites, notably those classified in the phospholipid (Figure 3)
and long-chain fatty acid classes (Figure 4), were present at lower
concentrations in the UQ than in controls, as were levels of certain
vitamin D metabolites and the anorectic pentapeptide, enterosta-
tin [52].
In comparisons between the Control and GDM groups, 392 of
3,552 metabolic features differed significantly. Of these 392
metabolites, 69 unique metabolic features were annotated
(Table 3). Here the picture was more evenly balanced, with about
one half of the metabolites in each class higher (35 of 69
metabolites) and the remainder lower in the UQ than the control
group.
For the UQ versus GDM comparison, 401 of 3552 metabolic
features differed significantly, of these, 72 unique metabolic
features were annotated, (Table 4). Many of the metabolites
annotated in Table 3 recurred in Table 4, but notably the
metabolite 2-Oxoglutaramate, an important biomarker of hepatic
encephalopathy and other hyperammonemic diseases [53,54] was
twice as abundant in previous GDM compared those in the UQ
subgroup (2.11 (0.79, 3.96; p= 0.015)). A notable fold change in
the metabolite N-(aminomethyl)urea was observed between the
groups (Table 3 and Table 4).
Discussion
The pathophysiological metabolic changes in the very early
stages of type 2 diabetes, before measurable hyperglycemia,
remain comparatively little known or understood. Our current
results provide compelling evidence for the occurrence of
significant metabolic defects that antedate the onset of hypergly-
cemia, even if marginal differences in glycemia well within the
normal range were present. These metabolic defects may exert
effects that can lead to or cause subsequent glucoregulatory
decompensation deteriorating to ‘hyperglycemia’, which currently
defines the disease.
The particular metabolic pathways suggested by this study are
defects in those regulating systemic lipid metabolism [55] and
hormone secretion/responsiveness [56]; they appear to antedate
and could therefore ‘cause’ or lead to overt hyperglycemia.
Hormones currently implicated in the development of T2DM
include the beta-cell hormones insulin and amylin [55,56], and the
adipocyte hormones leptin [57] and adiponectin [58]. Early
damage to blood vessels [1,59] and pancreatic islet beta-cells [60],
for example, provide evidence for metabolic defects that antedate
diabetes. Copper homeostasis and iron status are also related to
GDM [61–63]. For example, high body iron stores, leading to
unliganded iron, cause hydroxyl radical formation via Fenton
chemistry and are significantly associated with a greater risk of
T2DM [22,64–67]. Here, 29 of the women were included in a
vascular sub-study where there was a gradation of declining
endothelial function of resistance blood vessels ex-vivo, poorest in
the 12 of the 18 women with prior GDM studied here and less
marked in those with UQ, compared with controls defined the
same way [3]. Those vascular findings parallel the metabolic
changes reported here.
To address questions of what metabolic markers identify the
pathogenic pathways to T2DM and from them potential new
strategies for disease prevention, we compared the 2 at-risk groups
with controls to quantify specific metabolic differences between
groups. The data suggest that some pathogenic processes may
have begun by the time women reached the UQ state, with others
underway when they further deteriorate, previously indicated by
being GDM. Several distinct if overlapping molecular processes
may underpin these successive degrees of regulatory impairment
represented by the two increased-risk states. Dividing the complex
time-dependent process into stages produces artificial categories
but enables identification of earlier- and later-onset pathways.
Twenty-two months after their index pregnancy, when origi-
nally profiled by their glucose tolerance, the women had this status
re-assessed by fasting plasma glucose and hemoglobin A1c values.
In contrast to their within-pregnancy glucose tolerance, glycaemic
indices at re-testing were not different between the UQ and GDM
groups, although both were marginally defective compared to
controls, yet still within the usual, ‘currently normal’ glycaemic
range. Pair-wise between-group comparisons pinpointed relatively
circumscribed subsets of defined metabolite classes related to
elevated diabetes risk. Those metabolite classes perturbed in the
UQ compared with control women included: phospholipid
subclasses, in particular phosphatidylcholines; LCFA; LCFA-
carnitines; SCFA and SCFA-metabolites. Other perturbed classes
included diglycerides; bile acids; steroids; prostanoids; and amino
Figure 3. Phospholipids that differed significantly between control and UQ groups at 2-y follow-up (p,0.05). *Identification by
matching of retention time and accurate mass to authentic chemical standard.
doi:10.1371/journal.pone.0103217.g003
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acid metabolites. Most of these belong to lipid sub-classes. The
greatest differences here were in the acyl carnitine class.
Prominent differences in phosphatidylcholines were identified in
both the control/UQ and UQ/GDM contrasts. Diacyl-phospha-
tidylcholines has been shown to be independently associated with
increased risk of type 2 diabetes in a prospective study of type 2
diabetes patients in the European Prospective Investigation into
Cancer and Nutrition (EPIC)-Potsdam cohort [27]. Phospholipids
are highly insoluble in aqueous media so these molecules will have
originated in membranous structures in plasma, namely lipopro-
teins; this suggests that differences in phosphatidylcholine compo-
sition are related and could contribute to glucoregulatory
transitions preceding hyperglycemia. Alterations in additional
lipid classes including those of steroids/bile acids, and diglycerides
are also probably related to changes in lipoprotein metabolism.
Consistent with these findings, diabetes itself is associated with
prominent changes in plasma lipoprotein content [68,69]. This
disturbance in phospholipid metabolism cannot be localised or
characterised further here since the observed changes could reflect
alterations in any or all of the HDL, LDL, or VLDL fractions.
Prominent alterations in LDL-particle composition have previ-
ously been identified in diabetes pathogenesis [70], lipoprotein-
bound phospholipids are reportedly targets of glycoxidation-
mediated damage [71], and oxidized phospholipids can become
pathogenic [72,73]. Such direct effects of lipid alterations on blood
vessels possibly underlie the major benefits of statin treatment in
T2DM, although statins are also thought to be anti-inflammatory
[22,74]. Whether, and through what pathways, statins may lead to
increases in glycemia [17,18] remain unanswered questions
relevant to this early pathogenesis. Altered lipoproteins are also
implicated in the mechanisms that lead to or cause beta-cell
dysfunction in diabetes [75]. Follow-up proteomic and metabo-
lomic studies of purified lipoprotein fractions from different classes
of at-risk patients would now help identify the specific molecules
more clearly and may in time be useful in improving the
performance of classification models based on standard factors
[76]. The data here clearly point to early alteration in lipoprotein
metabolism in the chain of events that culminate in diabetes and
its complications.
A lysophospholipid-related signal may also be present, partic-
ularly in the UQ/GDM and control/GDM comparisons,
indicating the onset of pro-inflammatory stress, which contributes
to tissue damage. Plasma lyosphosphospholipid content is another
potential biomarker for monitoring oxidative damage caused, for
example [77] by perturbed regulation of catalytically-active copper
metabolism before and in diabetes [78]. Lysophospholipid
measurements could help monitor progression of tissue damage
in people at risk of developing diabetes, and perhaps the response
to preventive/therapeutic interventions.
Another significantly perturbed lipid-related signal here was for
LCFA and LCFA-carnitines. Both classes tended to be lower in the
UQ than in controls. Gall et al reported that medium-chain
acylcarnitines such as decanoylcarnitine decreased in concentra-
tion with increasing insulin resistance and dysglycemia [35]. In the
population-based Cooperative Health Research in the Region of
Augsburg (KORA) cohort, three metabolites, namely glycine,
lysophosphatidylcholine (LPC) (18:2) and acetylcarnitine had
significantly altered levels in IGT individuals as compared to
those with normal glucose tolerance [79]. Acylcarnitines are
biosynthesized solely in mitochondria, where they transport fatty
acids into the organelle for beta-oxidation, so decreases in their
plasma levels might reflect increased mitochondrial utilisation
[80]. Here, serum levels of both LCFA and LCFA-carnitines were
lower in UQ compared to control women, consistent with
increased rates of tissue fatty acid utilisation in the UQ group.
Such changes can occur in the glucose-sparing fuel economy that
emerges in diabetes [81]. Preferential fatty-acid utilisation may
contribute to systemic hyperglycemia as recognised long ago [82].
Our data indicate that such utilisation begins much earlier in the
pathogenic process than hitherto recognised. The lowering of
LCFA and LCFA-carnitines coincided with a small increase in
fasting plasma glucose in the UQ group, consistent with
substitution of LCFA for glucose in mitochondrial oxidation.
Perturbations in LCFA metabolism have been implicated in the
pathogenesis of beta-cell damage in diabetes [83]; the early onset
of altered LCFA here may lead to or cause beta-cell dysfunction/
damage [57]. Acyl carnitine levels were elevated in pregnant
women who went on to develop pre-eclampsia [34]. By contrast,
this pattern is no longer evident in the UQ/GDM comparison,
Figure 4. Long chain fatty acids that differed significantly between control and UQ groups at 2-y follow-up (p,0.05). PC,
phosphatidylcholine; PE, phosphatidylethanolamine; PG, glycerophosphoglycerol; PS, phosphatidylserine.
doi:10.1371/journal.pone.0103217.g004
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where LCFA tended to be higher, probably consistent with their
impaired mitochondrial oxidation, typical of insulin resistance in
the former (and fatter) GDM group.
Another complex metabolic alteration change more prominent
in the UQ/GDM comparison is a tendency to increased numbers
of SCFA and SCFA-metabolites. Elevated SCFA and SCFA-
metabolites suggest their defective utilisation, as in diabetes [81],
again occurring earlier than hitherto realised. Shikimate 3-
phosphate an obligatory intermediate in the anabolic pathway
for biosynthesis of the essential aromatic amino acids, is potentially
a microbial metabolite not produced in human cellular metabo-
lism [84]. Some SCFA-metabolites identified may originate from
microbial biosynthesis. The identification of microbial metabolites
in human plasma with possible links to defective glucoregulation
could point to between-group differences in their production by
gut microflora and/or uptake from the gut. Other identified
metabolic features, as in terpenoid/quinones and teasterone/
typhasterol may be of plant origin, consistent with possible
differences in dietary intake and/or uptake from the gut.
We also found (Table 1) that significantly lower circulating
adiponectin levels occurred before measurable alterations in
insulin or leptin levels. Adiponectin deficiency occurs from
infancy, as found in the children of this cohort [85] and may
influence GDM [28] and T2DM [86–88]. It is associated with
defective glycosylation and functionality, such as impaired ability
to stimulate hepatic or muscle mitochondrial fatty acid oxidation
via AMP kinase [58,89]. Adiponectin deficiency could provide a
central link between perturbed phosphatidylcholine metabolism
and mitochondrial lipid utilisation here. However, whether
changes in production/secretion and/or signalling of known
hormones including adiponectin really antedate or rather result
from the described metabolic changes remains uncertain. It is
certainly known that adiponectin deficiency can cause these
changes but together with the exact nature and origin of the
adiponectin deficiency observed here, requires further longitudinal
study.
In summary, we identified here a rather consistent pattern of
metabolic perturbations in groups of women whose diabetes risk
was stratified a priori by differences in their degree of
glucoregulatory impairment during a previous pregnancy. The
data point to a time-line in the molecular pathologies ultimately
leading to type 2 diabetes; the changes found in the control/UQ
comparison likely precede those in the UQ/GDM comparison
(e.g. perturbed plasma phospholipids and altered lipoprotein
metabolism). A second early alteration was the relative fall in
plasma LCFA and LCFA-carnitines, along with minor increases in
fasting plasma glucose and HbA1c levels. Those are consistent with
a glucose-sparing mitochondrial fuel economy, related to the
increased abdominal circumference in the UQ and GDM groups.
Many changes occurred in clusters of metabolite classes, for
example phospholipids, lysophospholipids, LCFA, LCFA-carni-
tines, and SCFA/SCFA-metabolites, pointing to mechanisms that
affect large subsets of these metabolite classes (e.g. transcription
factors), long before the emergence of overt disease. Differences in
relative timings of activation in different potential pathways to the
onset/progression of T2DM pathogenesis were also observed.
Modified lysophospholipid metabolism possibly implies elevated
pro-inflammatory stress; lowered LCFA/LCFA-carnitine levels
are consistent with early metabolic fuel substitution leading to
preferential mitochondrial oxidation of LCFA as opposed to
glucose, providing an early hyperglycemic stimulus; a widespread
increase in SCFA/SCFA-metabolites suggest potential early
defects in their generation and/or defective mitochondrial
utilisation.
Finally, we found early adiponectin deficiency which may
initiate or contribute to several of the metabolic disturbances, The
results point to a probable defect in adipose tissue regulation
contributing to the initiation of T2DM pathogenesis; further
characterisation of the early changes in adiponectin synthesis and
post-translational modifications and its causes will be useful. Our
current conclusions are reminiscent in several respects of those
from a recent study of the antecedents of type 1 diabetes wherein
dysregulation of lipid and amino acid metabolism preceded islet
autoimmunity in children who later progressed to overt disease
[37].
Our study paves the way for targeted investigation of the
pathogenic biochemical pathways that lead to or cause type 2
diabetes and more effective prevention and therapy [90], notably
of blood vessel damage. Further longitudinal studies of diabetes
development as we are doing here will be needed for assessing
those at risk in general populations. Our study highlights the
important role of metabolic profiling in discovery studies related to
diabetes. Although metabolite identifications are not definitive
they provide mechanistic information to guide further targeted
studies. The major perturbations in this hypothesis-generating
stage affected large subsets of metabolite classes showing co-
variation between metabolites. Therefore, no corrections for
multiple comparisons were applied. Finally, whether these patterns
of metabolic derangements after prior GDM may lead to or cause
the T2DM in general populations needs testing.
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